Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4652-4654
10.1182/blood-2022-159141